What amgen uk & ie does

Amgen UK & Ireland is the UK and Republic of Ireland operating subsidiary of Amgen Inc. (NASDAQ: AMGN), one of the world's largest independent biotechnology companies founded in 1980 as Applied Molecular Genetics. Headquartered at Cambridge Science Park (over 25 years of presence) with a Development Centre in Uxbridge opened in 2007, the subsidiary employs approximately 650 staff in the UK and is described by the parent as one of its largest sites outside California, serving as the European hub for research and development. The legal entities are Amgen Limited (England and Wales) and Amgen Ireland Limited (Republic of Ireland).

Amgen UK develops, supplies, and supports a portfolio of 19 branded biologic prescription medicines spanning four therapeutic areas: oncology and haematology (BLINCYTO, Kyprolis, Vectibix, LUMYKRAS, IMDYLLTRA, IMLYGIC, Nplate), inflammation (AMGEVITA, OTEZLA, WEZENLA), bone health (Prolia, XGEVA), and cardiovascular and rare disease (Repatha, BEKEMV, Mimpara, Parsabiv, Aranesp, Neulasta, NEUPOGEN). The portfolio also includes one of the world's largest biosimilars franchises. Manufacturing relies on biologic production using living cells in bioreactors up to 20,000 litres, with over 250 quality checks per product, supported by R&D capabilities including Generative Biology (AI/ML plus biology for protein drug discovery) and the deCODE genetics population genomics platform.

Revenue is generated through direct prescription-medicine sales to the NHS and hospital systems via an enterprise field-sales motion, with orders managed through the Amgen Direct online portal. The company engages in collaborative working agreements and joint working projects with named NHS partners (Belfast HSCT, University Hospitals Birmingham, Guy's & St Thomas', Manchester University NHSFT, Sheffield Teaching Hospitals, Hywel Dda UHB) covering medicines optimisation, service redesign, and population health initiatives such as the QuicDNA liquid biopsy lung cancer programme and Next Generation Population Health cardiovascular risk modelling. The UK entity is fully ABPI Code-compliant, holds UK Binding Corporate Rules for cross-border data transfers, and operates the Amgen Foundation's science-education programmes in the UK.

Name

amgen uk & ie

Legal name

Amgen Limited (UK entity); Amgen Ireland Limited (Ireland entity)

Website

https://amgen.co.uk

Company type

Private

Founded year

1980

Operating status

Operating

Short description

Amgen UK & Ireland is the UK and Ireland subsidiary of Amgen Inc., developing and supplying biologic medicines in oncology, inflammation, bone health, and cardiovascular disease to NHS Trusts, hospitals, and specialists through direct enterprise sales.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Biologic medicines
• Oncology therapeutics
• Biosimilars portfolio
• Bone health treatments
• Cardiovascular biologics

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Prescription Biologic Medicines: Amgen discovers, develops, manufactures and delivers innovative biologic medicines to patients with serious illnesses. Revenue is generated through product sales of prescription medicines to healthcare systems and patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Amgen UK & IE discovers (via the global Amgen pipeline), supplies, and supports the use of biologic prescription medicines to UK and Irish healthcare providers. Its portfolio includes 19 branded biologics and biosimilars covering oncology, haematology, inflammation, bone health, cardiovascular disease, and rare diseases, delivered through direct supply to NHS Trusts and hospitals and supported by field medical teams. The Cambridge headquarters and Uxbridge Development Centre also host European R&D activities for the parent group.

Product overview

Amgen UK is a biotechnology company offering a diversified portfolio of innovative biologic medicines and biosimilars. The company operates across four main therapeutic areas: oncology and hematology, inflammation, bone health, and cardiovascular disease. Its portfolio includes 19 branded prescription medicines including targeted cancer therapies (BLINCYTO, Kyprolis, Vectibix, LUMYKRAS), supportive care products (NEUPOGEN, Neulasta, Nplate), inflammation treatments (AMGEVITA, OTEZLA, WEZENLA), bone health therapies (Prolia, XGEVA), cardiovascular medicines (Repatha), and rare disease treatments (BEKEMV, Mimpara, Parsabiv). The portfolio also includes breakthrough therapies (IMDYLLTRA for small cell lung cancer, IMLYGIC for melanoma). Amgen manufactures biologic medicines using living cells through complex biomanufacturing processes and offers both innovator biologics and biosimilars backed by over 40 years of biotechnology experience.

Differentiator

Problem solved

Functional benefit

Products and services

• AMGEVITA (adalimumab) A biosimilar of adalimumab used for treating inflammatory conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease; supplied to NHS hospitals for specialist prescribing.
• Aranesp (darbepoetin alfa) An erythropoiesis-stimulating agent used to treat anaemia, particularly in patients with chronic kidney disease or cancer; supplied to NHS hospitals and specialist centres.
• BEKEMV (eculizumab) A monoclonal antibody used for treating paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS); supplied to NHS specialist centres.
• BLINCYTO (blinatumomab) A bispecific T-cell engager (BiTE) antibody used for treating acute lymphoblastic leukaemia (ALL); supplied to NHS specialist oncology centres.
• IMDYLLTRA (tarlatamab) A bispecific antibody targeting DLL3 for treating small cell lung cancer; supplied to specialist oncology centres.
• IMLYGIC (talimogene laherparepvec) An oncolytic viral therapy used for treating melanoma lesions in the skin and lymph nodes; supplied to specialist oncology centres.
• Kyprolis (carfilzomib) A proteasome inhibitor used for treating multiple myeloma in patients who have received at least one prior therapy; supplied to NHS specialist haematology centres.
• LUMYKRAS (sotorasib) A KRAS G12C inhibitor used for treating non-small cell lung cancer with KRAS G12C mutations; supplied to specialist oncology centres.
• Mimpara (cinacalcet HCl) A calcimimetic agent used for treating secondary hyperparathyroidism in patients with chronic kidney disease; supplied to NHS renal units.
• NEUPOGEN (filgrastim) A filgrastim formulation used to reduce the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy; supplied to NHS oncology centres.
• Neulasta (pegfilgrastim) A pegylated filgrastim formulation used to reduce the duration of neutropenia and febrile neutropenia in patients receiving chemotherapy; supplied to NHS oncology centres.
• Nplate (romiplostim) A thrombopoietin receptor agonist used for treating immune thrombocytopenia (ITP) in adult patients; supplied to NHS specialist haematology centres.
• OTEZLA (apremilast) A PDE4 inhibitor used for treating psoriatic arthritis and moderate to severe plaque psoriasis; supplied to NHS specialist dermatology and rheumatology centres.
• Parsabiv (etelcalcetide) A calcimimetic agent used for treating secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis; supplied to NHS renal units.
• Prolia (denosumab) A RANKL inhibitor used for treating osteoporosis in postmenopausal women and men at increased risk of fracture; supplied to NHS bone health services.
• Repatha (evolocumab) A PCSK9 inhibitor used for treating hypercholesterolaemia and reducing cardiovascular events; supplied to NHS lipid clinics and cardiology services.
• Vectibix (panitumumab) An EGFR inhibitor used for treating metastatic colorectal cancer with wild-type RAS tumours; supplied to NHS specialist oncology centres.
• WEZENLA (ustekinumab) A biosimilar of ustekinumab used for treating plaque psoriasis, psoriatic arthritis, and Crohn's disease; supplied to NHS specialist centres.
• XGEVA (denosumab) A RANKL inhibitor used for preventing skeletal-related events in patients with bone metastases from solid tumours and for treating giant cell tumour of bone; supplied to NHS oncology centres.

Quantifiable outcome

• More than 750,000 people in 65+ countries prescribed Amgen biosimilars
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• All-Wales Medical Genomic Services (AWMGS)coreStrategic or Co-development Partner · 1 March 2023QuicDNA project partnership for accelerating lung cancer diagnosis through innovative liquid biopsy (ctDNA) testing. Multiple Welsh Health Boards involved.
• Khan AcademyminorStrategic or Co-development Partner · 1 January 2015Amgen Foundation is exclusive sponsor of Khan Academy's online biology resources since 2015, covering high school and college-level biology content.
• Amgen Scholars - European Programme (University of Cambridge)minorStrategic or Co-development Partner · 1 January 2006Undergraduate summer research experience programme hosted at 24 premier institutions worldwide. European programme symposium held at University of Cambridge annually.
• Belfast Health & Social Care TrustcoreStrategic or Co-development PartnerCollaborative working agreement focused on patient care improvement initiatives and medicines optimisation.
• University Hospitals Birmingham NHS Foundation TrustcoreStrategic or Co-development PartnerCollaborative working project for improving patient outcomes and healthcare service delivery.
• Guy's & St Thomas' NHS Foundation TrustcoreStrategic or Co-development PartnerCollaborative working partnership for patient care initiatives.
• Manchester University NHS Foundation TrustcoreStrategic or Co-development PartnerCollaborative working agreement for healthcare improvement projects.
• Sheffield Teaching Hospitals NHS Foundation TrustcoreStrategic or Co-development PartnerCompleted collaborative working outcomes project for patient care improvement.
• Hywel Dda University Health BoardcoreStrategic or Co-development PartnerNext Generation Population Health project - cardiovascular disease risk prediction and prevention initiative in partnership with Swansea Bay University Health Board and Swansea University.
• Swansea UniversitycoreStrategic or Co-development PartnerAcademic partnership in Next Generation Population Health project for cardiovascular disease research.
• Patient Advocacy Groups (UK)coreStrategic or Co-development PartnerPartnerships with patient advocacy groups to support programmes that benefit patients. Annual funding disclosures made publicly available. Includes various UK patient organisations.
• Amgen Biotech Experience - UK Secondary SchoolsminorStrategic or Co-development PartnerScience education programme providing teachers with professional development and education materials, loaning research-grade equipment to high schools free of charge. Over one million students reached worldwide.
• LabXchange (Harvard University)minorStrategic or Co-development PartnerFree online science learning platform developed at Harvard University, funded by Amgen Foundation. Provides personalised instruction and virtual lab experiences.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sanofi UK: UK subsidiary of French pharmaceutical major Sanofi with biologic medicines in immunology, rare diseases, and oncology. Competes with Amgen UK in inflammatory disease biologics and similar NHS hospital supply arrangements.
• Bristol-Myers Squibb UK: UK subsidiary of Bristol-Myers Squibb, a major biologic medicines company in oncology, immunology, and cardiovascular disease. Direct competitor in NHS hospital specialty markets for cancer biologics and similar BiTE technology (BLINCYTO competitive set).
• Roche UK: UK subsidiary of Swiss pharmaceutical giant Roche, a global leader in biologic medicines for oncology and immunology. Direct competitor in NHS hospital channels for cancer biologics and similar biosimilars portfolio.
• Johnson & Johnson Innovative Medicine UK: UK subsidiary of Johnson & Johnson's pharmaceutical segment with biologic medicines in oncology, immunology, and pulmonary hypertension. Competes with Amgen UK in similar specialty hospital markets through NHS supply channels.
• Novartis UK: UK subsidiary of Swiss pharmaceutical major Novartis with strong biologic medicines presence in oncology and immunology. Competes with Amgen UK in similar therapeutic areas through NHS hospital supply arrangements.
• AbbVie UK: UK subsidiary of AbbVie, a global leader in biologic medicines particularly in immunology (Humira franchise) and oncology. Direct competitor in inflammatory disease biologic market and emerging biosimilar competitor in UK.
• Pfizer UK: UK subsidiary of global pharmaceutical leader Pfizer with significant biologic medicines portfolio and growing biosimilars business. Competes with Amgen UK in oncology, inflammation, and rare disease biologic markets via NHS channels.
• AstraZeneca UK: UK-headquartered global pharmaceutical company with a major biologic medicines franchise in oncology, cardiovascular, and respiratory disease. Direct overlap with Amgen UK in supplying biologic medicines to NHS hospitals across multiple therapeutic areas.
• Eli Lilly UK: UK subsidiary of Eli Lilly with growing biologic medicines portfolio in oncology, immunology, and diabetes/obesity. Increasingly competes with Amgen UK in NHS specialty channels, particularly in cardiometabolic and inflammation areas.
• GSK UK: UK-headquartered global pharmaceutical company with biologic medicines in oncology, immunology, and rare diseases. Competes with Amgen UK in NHS hospital specialty channels and has overlapping R&D infrastructure in UK life sciences clusters.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about amgen uk & ie